Camlin Fine Sciences (CFS) provides solutions like antioxidants, performance chemicals, and aroma ingredients for the extension of shelf life. Its diphenol derivatives are used in industries like food, fragrances, biofuel, aquaculture, pharmaceuticals, petrochemicals, agrochemicals, and dyes, among others. The company's specialities include food-grade antioxidants, antimicrobials, toxin binders, emulsifier blends, growth promoters, traditional and natural antioxidants, and more. In addition to manufacturing in India, its manufacturing facilities are located in China, Italy, Brazil, Mexico, and the USA. Its R&D facilities can also be found in Europe, the Americas, and Asia. The company is currently headquartered in Mumbai and led by Ashish Subhash Dandekar.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 1576 -12.0% | 1790 22.8% | 1459 24.2% | 1175 9.6% | 1072 15.7% | 927 26.1% | 735 26.2% | 582 7.7% | 541 -3.2% | 559 10.0% | 508 24.5% | 408 8.1% | 378 102.8% | 186 32.0% | 141 18.4% | 119 - |
Net Operating Income (INR Cr) | 1613 -4.07% | 1682 19.08% | 1412 18.95% | 1187 13.15% | 1049 17.60% | 892 23.81% | 721 34.96% | 534 9.11% | 489 -12.35% | 558 9.75% | 509 36.15% | 374 11.45% | 335 95.29% | 172 22.38% | 140 34.74% | 104 28.10% |
Profit (INR Cr) | -93 - | 52 -14.1% | 61 19.1% | 51 68.1% | 30 - | 1 - | -30 - | -11 - | 36 -34.9% | 55 91.7% | 29 90.1% | 15 298.4% | 4 -46.7% | 7 487.6% | 1 -50.6% | 2 - |
Assets (INR Cr) | 1546 -5.2% | 1630 13.5% | 1436 13.4% | 1266 26.4% | 1001 12.1% | 894 10.6% | 808 43.5% | 563 57.1% | 358 21.0% | 296 21.4% | 244 27.8% | 191 7.5% | 178 55.5% | 114 50.8% | 76 31.3% | 58 - |
Net Worth (INR Cr) | 820 8.5% | 756 13.6% | 665 22.5% | 543 34.7% | 403 8.7% | 371 -0.1% | 371 74.6% | 213 20.6% | 176 30.7% | 135 44.6% | 93 42.7% | 65 23.6% | 53 13.9% | 46 59.9% | 29 -0.2% | 29 4.6% |
Employee Cost (INR Cr) | 179 9.9% | 163 12.1% | 145 20.5% | 120 20.7% | 100 13.5% | 88 20.6% | 73 19.3% | 61 52.5% | 40 -1.3% | 41 18.1% | 34 13.7% | 30 27.6% | 24 127.6% | 10 34.0% | 8 25.5% | 6 - |
Interest Cost (INR Cr) | 70 | 66 | 41 | 42 | 48 | 41 | 32 | 31 | 24 | 24 | 25 | 20 | 17 | 9 | 7 | 6 |
Cash & Bank Balance (INR Cr) | 94 | 99 | 142 | 138 | 65 | 103 | 48 | 31 | 19 | 19 | 16 | 26 | 10 | 13 | 4 | 2 |
Total Debt (INR Cr) | 683 | 801 | 646 | 550 | 539 | 461 | 373 | 331 | 180 | 160 | 150 | 126 | 125 | 68 | 47 | 28 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit As % Of Revenues | - | 2.9% | 4.2% | 4.3% | 2.8% | 0.1% | - | - | 6.6% | 9.9% | 5.7% | 3.7% | 1.0% | 3.8% | 0.9% | 2.1% |
Profit As % Of Assets | - | 3.2% | 4.2% | 4.0% | 3.0% | 0.1% | - | - | 10.0% | 18.6% | 11.8% | 7.9% | 2.1% | 6.2% | 1.6% | 4.2% |
Profit As % Of Networth | - | 6.9% | 9.1% | 9.4% | 7.5% | 0.2% | - | - | 20.3% | 40.8% | 30.8% | 23.1% | 7.2% | 15.3% | 4.2% | 8.4% |
Interest Cost to EBITDA % | 207.2% | 32.6% | 25.9% | 22.7% | 35.2% | 56.2% | 198.8% | 96.1% | 28.0% | 28.3% | 40.0% | 42.8% | 56.9% | 59.0% | 54.0% | 43.7% |
Debt to Equity Ratio | 0.83 | 1.06 | 0.97 | 1.01 | 1.34 | 1.24 | 1.00 | 1.56 | 1.02 | 1.19 | 1.61 | 1.92 | 2.36 | 1.46 | 1.60 | 0.97 |
RONW | - | 6.3% | 10.0% | 13.8% | 7.7% | 0.8% | - | - | 23.0% | 48.2% | 36.2% | 25.6% | 6.4% | 6.2% | 3.7% | 7.5% |
ROCE | 1.4% | 10.8% | 11.1% | 14.5% | 11.9% | 7.3% | 0.2% | 5.4% | 22.8% | 28.4% | 27.4% | 23.7% | 17.5% | 12.3% | 15.2% | 18.0% |